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AbstrACt
background Prostate cancer (PCa) has been 
under investigation as a target for antigen- specific 
immunotherapies in metastatic disease settings for 
the last two decades leading to a licensure of the first 
therapeutic cancer vaccine, Sipuleucel- T, in 2010. 
However, neither Sipuleucel- T nor other experimental PCa 
vaccines that emerged later induce strong T- cell immunity.
Methods In this first- in- man study, VANCE, we evaluated 
a novel vaccination platform based on two replication- 
deficient viruses, chimpanzee adenovirus (ChAd) and MVA 
(Modified Vaccinia Ankara), targeting the oncofetal self- 
antigen 5T4 in early stage PCa. Forty patients, either newly 
diagnosed with early- stage PCa and scheduled for radical 
prostatectomy or patients with stable disease on an active 
surveillance protocol, were recruited to the study to assess 
the vaccine safety and T- cell immunogenicity. Secondary 
and exploratory endpoints included immune infiltration 
into the prostate, prostate- specific antigen (PSA) change, 
and assessment of phenotype and functionality of antigen- 
specific T cells.
results The vaccine had an excellent safety profile. 
Vaccination- induced 5T4- specific T- cell responses were 
measured in blood by ex vivo IFN-γ ELISpot and were 
detected in the majority of patients with a mean level in 
responders of 198 spot- forming cells per million peripheral 
blood mononuclear cells. Flow cytometry analysis 
demonstrated the presence of both CD8+ and CD4+ 
polyfunctional 5T4- specific T cells in the circulation. 5T4- 
reactive tumor- infiltrating lymphocytes were isolated from 
post- treatment prostate tissue. Some of the patients had 
a transient PSA rise 2–8 weeks following vaccination, 
possibly indicating an inflammatory response in the target 
organ.
Conclusions An excellent safety profile and T- cell 
responses elicited in the circulation and also detected in 
the prostate gland support the evaluation of the ChAdOx1- 
MVA 5T4 vaccine in efficacy trials. It remains to be seen 
if this vaccination strategy generates immune responses 
of sufficient magnitude to mediate clinical efficacy and 
whether it can be effective in late- stage PCa settings, as 
a monotherapy in advanced disease or as part of multi- 
modality PCa therapy. To address these questions, the 
phase I/II trial, ADVANCE, is currently recruiting patients 
with intermediate- risk PCa, and patients with advanced 
metastatic castration- resistant PCa, to receive this vaccine 
in combination with nivolumab.
trial registration The trial was registered with the U.S. 
National Institutes of Health (NIH) Clinical Trials Registry ( 
ClinicalTrials. gov identifier NCT02390063).
bACkground
Prostate cancer (PCa) is the most common 
non- cutaneous malignancy in men and the 
second leading cause of male cancer- related 
death in the Western world.1 If the disease 
progresses to metastatic castration- resistant 
prostate cancer (mCRPC), the current treat-
ment options are mainly palliative. Two next- 
generation hormonal agents, abiraterone 
and enzalutamide, have improved treatment 
of mCRPC; however, resistance to these drugs 
eventually ensues, with the disease becoming 
lethal. Cancer immunotherapy may be a 
viable option for treatment of patients with 
advanced stage PCa. To date, the only thera-
peutic cancer vaccine to be approved by the 
US Food and Drug Administration is Sipuleu-
cel- T, and is indicated for patients with asymp-
tomatic or minimally symptomatic mCRPC.2 
This cell- based immunotherapy targeting the 
prostatic acid phosphatase (PAP) has shown 
modest, though statistically significant, effi-
cacy in clinical trials, increasing overall 
survival in treated patients by 4 months. 
However, no effect on time to tumor progres-
sion compared with the placebo group 
has been observed and the induced T- cell 
responses appeared weak.3
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Another vaccine, ProstVac, targeting prostate- specific 
antigen (PSA) and composed of two poxvirus vectors, 
demonstrated an 8.5- month increase in median overall 
survival compared with the control group in the phase 
II study in mCRPC. However, T- cell immune responses 
against the vaccine- encoded antigen were modest,4 and 
no clinical efficacy was observed in the ProstVac phase 
III trial.5
In the current study, we targeted the tumor antigen 
5T4 using an immunization platform based on the ChAd 
prime and MVA boost. 5T4 is an oncofetal antigen, also 
known as trophoblast glycoprotein, typically expressed 
during embryonic development, while its expression 
is very limited in normal adult tissue.6 However, 5T4 
was reported to be upregulated in a wide range of solid 
malignancies, including but not limited to colon, kidney, 
lung, breast, stomach, ovaries and prostate cancer, and 
its expression has been correlated with poor prognosis in 
multiple indications,7–11 making 5T4 a promising target 
for a cancer vaccine.
ChAd- MVA vaccination platform, developed in our 
laboratories over a decade ago, has been shown to be 
the most powerful approach for inducing polyfunctional 
protective T- cell responses against antigens from diverse 
human pathogens in clinical trials.12–18 Preclinical evalua-
tion demonstrated tumor protective efficacy of this vacci-
nation strategy in murine prostate cancer models,19 20 
thus providing a rationale for a phase I clinical study. 
Here, we report the results of the first- in- human study 
VANCE, evaluating the safety of ChAdOx1- MVA 5T4 
vaccine in early- stage PCa. The induction of antigen- 
specific immune responses in both the blood and the 
prostate gland, the effect of low- dose cyclophosphamide 
(CTX) preconditioning on the immune responses and 
changes in serum concentration of PSA are also reported. 
Vaccine efficacy assessments are effectively not possible in 
this trial design because the selected patient cohort either 
had a curative surgical treatment shortly after vaccination 
or a subsequent very low risk of recurrent disease that 
would require a long follow- up period beyond the dura-




VANCE was a phase I randomized open- label study 
designed to assess the safety and immunogenicity of 
ChAdOx1- MVA 5T4 vaccine with and without low- dose 
CTX in low- risk and intermediate- risk localized PCa. 
Participants were enrolled at the Oxford University Hospi-
tals NHS Foundation Trust and the Sheffield Teaching 
Hospitals NHS Foundation Trust, in the UK.
The sample size was chosen to allow an initial descrip-
tive report of the safety and immunogenicity of the 
vaccine in a first- in- human trial.
Randomization was performed by an independent stat-
istician at the Centre for Statistics in Medicine, Oxford 
University. Allocation was performed using a balanced- 
block stratified randomization.
study population
The target population for this study was men newly diag-
nosed with low- risk or intermediate- risk PCa who had 
chosen radical prostatectomy (RP) as their treatment 
option, and men with low- volume low- risk prostate cancer 
on an active surveillance (AS) program and stable for at 
least a year. Patients eligible for the study had histologi-
cally confirmed PCa, PSA ≤20 ng/mL, Gleason score ≤7, 
clinical stage disease ≤T2 c and no evidence of metastases.
Exclusion criteria included history of immunodefi-
ciency disease, systemic immunosuppression, allergic 
response to previous vaccinia virus vaccinations, seropos-
itivity for hepatitis B surface antigen, hepatitis C virus or 
HIV.
study products
Design and construction of ChAdOx1.5T4 vaccine has 
been described previously.20 ChAdOx1.5T4 was manu-
factured to clinical good manufacturing practice by the 
Clinical Biomanufacturing Facility (University of Oxford, 
Oxford, UK). The ChAdOx1.5T4 vaccine has been 
administered at the dose of 2.5×1010 virus particles (vp). 
MVA.5T4 vaccine was manufactured and supplied for the 
trial by Oxford BioMedica Ltd (TroVax), and has been 
described previously.21 The MVA.5T4 vaccine has been 
administered at the dose of 2.0×109 TCID50 (equivalent to 
1.2×108 plaque- forming units (pfu)). Both vaccines were 
administered by intramuscular injection in the thigh.
CTX (manufactured by Baxter) was self- administered 
orally at 50 mg twice a day for a 7- day cycle before each 
vaccination.
study procedures
Following screening, patients in the surgical arms were 
randomly allocated to six groups. Participants in groups 1 
and 2 received one ChAdOx1.5T4 immunization followed 
by two MVA.5T4 boosts 4 weeks apart and underwent RP 
at week 12 post- enrollment. Participants in groups 3 and 
4 received three MVA.5T4 immunizations 4 weeks apart 
and also underwent RP at week 12 post- enrollment. This 
immunization schedule was termed a “standard” vaccina-
tion regimen. Participants in groups 5 and 6 were admin-
istered with ChAdOx1.5T4 vaccine followed by MVA.5T4 
vaccination 1 week later and underwent RP at week 4 post- 
enrollment. This immunization schedule was termed an 
“accelerated” vaccination regimen. Patients on the AS 
program were randomized to groups 7 and 8 and received 
an accelerated vaccination regimen followed by on- study 
prostate biopsy at week 10 post- enrollment. The partic-
ipants in groups 2, 4, 6 and 8 received an oral course of 
low- dose CTX for 7 days prior to each immunization. The 
study treatment schedule is outlined in online supple-
mentary figure S1.
Blood samples were drawn and clinical assessments 
conducted for safety, immunology and PSA monitoring 
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prior to vaccination at day 0 and at each scheduled clin-
ical time point following enrollment.
Fresh prostate tissue specimens were collected from 
surgical RP specimens and from on- study biopsies in 
AS patients for analysis of post- vaccination immune cell 
subsets within the prostate tissue following treatment.
endpoints
Primary objectives of the study were safety of 
ChAdOx1- MVA 5T4 vaccination and the induction 
of immune responses to the vaccine- encoded tumor- 
associated antigen 5T4 in the blood following treatment. 
Secondary objectives of the study included comparative 
immunogenicity assessment of the standard and accel-
erated vaccination regimens, the effect of CTX precon-
ditioning on the magnitude of immune responses, the 
effect of vaccination on the immune cells in the tumor 
and serum PSA change during the study.
ex vivo IFn-γ eLIspot
Ex vivo IFN-γ ELISpot assay was performed at each sched-
uled time point in order to assess vaccine- induced immune 
responses. Briefly, 2.5×105 freshly isolated peripheral 
blood mononuclear cells (PBMCs) was plated in 96- well 
PVDF plates pre- coated with anti- IFN-γ antibody and stim-
ulated with eight individual pools each consisting of 10–12 
15mer peptides overlapping by 10 amino acids, spanning 
the complete 5T4 protein sequence. Unstimulated cells 
were used as a background control and Staphylococcus 
enterotoxin B (SEB) and CMV/Epstein- Barr/Flu peptide 
mix (Mabtech AB) were used as positive controls. After 
18–24 hours of incubation, plates were developed and 
the number of IFN-γ-producing cells (spot- forming cells, 
SFCs) was evaluated using an automated ELISpot reader 
(AID). 5T4- specific response was deemed to be posi-
tive at any time point when the mean number of SFCs 
per 1 million PBMCs was at least 40, and the number of 
spots per well at least two times the background. If a pre- 
existing T- cell response was detected, a positive response 
due to vaccination was reported if the post immunization 
response was ≥2- fold the response determined before 
immunization. Positive responses to individual pools were 
summed to give final SFC values per million PBMCs.
In vitro culture of PbMCs and tumor-infiltrating lymphocytes 
(tILs)
PBMCs and TILs were cultured in vitro to expand 
5T4- specific T cells. Briefly, 3×106 freshly isolated 
PBMCs/mL was plated in complete medium with 
or without total 5T4 peptide pool (5 µg /mL) in the 
presence of recombinant human IL-7 (rhIL-7) (25 ng/
mL). Every 3–4 days, the medium was replaced and 
rhIL-2 (100 U/mL) added to the cultures. PBMCs were 
harvested after 2 weeks and incubated overnight at 
37°C before further analysis. To obtain TIL cultures, 
prostate tissue specimens were cut into small pieces 
and cultured in the presence of rhIL-2 (6000 U/mL) as 
described previously.22 TIL medium was replaced every 
2–3 days and the total 5T4 peptide pool was added when 
immune cell cultures entered an exponential growth 
phase. TILs were typically harvested 1 week post- 5T4 
stimulation for further analysis.
Flow cytometric analysis
In vitro cultured PBMCs and TILs were incubated with 
1 µg/mL of co- stimulatory antibodies αCD28/αCD49d 
(eBioscience) followed by stimulation in 96- well plates 
with complete medium, SEB (1 µg/mL) or total 5T4 
peptide pool (5 µg/mL). Following a 2- hour incubation, 
brefeldin A and monensin (BD Bioscience) were added 
and cells were incubated overnight at 37°C. PBMCs were 
stained with surface antibodies, fixed/permeabilized and 
incubated with intracellular antibodies (online supple-
mentary table S1). Dead cells were discriminated by live/
dead fixable staining (Life Technologies). Samples were 
acquired on an LSRII flow cytometer and analyzed with 
FlowJo software.
Patients were deemed to be “responders” when the 
percentages of IFN-γ+ΤΝF-α+CD4+and CD8+ T cells 
after stimulation were higher than 0.02 and were at least 
2- fold the background on analysis in at least one time 
point post- vaccination. In addition, for cultured PBMCs 
the delta values (5T4 value–background value) had to be 
≥2- fold the corresponding pre- vaccination baseline delta 
value.
tissue biopsy evaluation
Archival diagnostic biopsies from AS patients collected 
within 1 year prior to enrollment, and on- study template 
or targeted biopsies obtained at week 10 post- enrollment, 
were evaluated. Tissue sections were stained immuno-
histochemically for expression of CD3 (clone LN10; 
Leica) and CD8 (clone C8/144B; Dako) at the ISO 15189 
accredited NHS Cellular Pathology Laboratory at Oxford 
University Hospitals NHS Foundation Trust (Oxford, 
UK). CD3+ and CD8+ T cells were enumerated according 
to the Tissue Phenomics approach employing a visual 
context random forest algorithm23 by Definiens GmbH 
(Munich, Germany). Epithelial and stromal regions were 
segmented via an in- house, pre- trained convolutional 
neural network24 and cell densities were calculated as 
the number of marker- positive cells per reference area 
(mm2).
data presentation and statistical analysis
Safety data are presented according to the frequency, 
severity and duration of solicited local and systemic reac-
togenicity signs and symptoms for 7 days following vacci-
nation. Unsolicited adverse events (AEs) were recorded 
for 4 weeks post- vaccination. Statistical analysis of immu-
nogenicity data was conducted using GraphPad Prism 
V.8. Comparisons between datasets were performed using 
non- parametric tests, as detailed in the figure legends. All 
p values are two sided and considered statistically signifi-
cant if p value <0.05.
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Figure 1 CONSORT flow diagram. Flow chart showing patients’ participation in VANCE trial study from screening, enrollment, 
allocation, follow- up and analysis. AS, active surveillance; CTX, cyclophosphamide; RP, radical prostatectomy.
resuLts
study participants and safety analysis
Forty patients were enrolled into the VANCE random-
ized open- label phase I study between October 26, 2015 
and October 19, 2017, with 39 participants completing 
the study treatment and eligible for analysis (figure 1). 
Median age, clinical stage and Gleason score of trial 
participants are presented in online supplementary table 
S2. VANCE clinical trial design is presented in online 
supplementary figure S1.
ChAdOx1.5T4 and MVA.5T4 vaccines were well toler-
ated. The majority of reported AEs related to vaccinations 
were mild in intensity (92%) and were consistent with 
side effects observed for these vectors in other clinical 
trials. Mild to moderate pain at injection site was reported 
by ~50% of patients. The majority of systemic AEs were 
graded as mild. Among the common systemic AEs 
usually seen post–replication- incompetent viral- vectored 
vaccines, feverishness, myalgia and fatigue were the most 
frequently reported, affecting 59%, 70% and 72% of indi-
viduals, respectively, and usually were resolved within 7 
days post- vaccination.
There were no reported serious adverse events (SAEs) 
related to the vaccines. The two reported SAEs, hospital 
admissions due to an episode of hematemesis and an 
aortic surgery caused by ascending aortic aneurysm, were 
considered unrelated to the vaccines.
Vaccine-induced t-cell responses in the blood
Twenty- five of 39 (64%) patients who completed the 
vaccination course and were eligible for analysis mounted 
5T4- specific T- cell immune responses at one or more 
blood sampling timepoints, as measured by ex vivo IFN-γ 
ELISpot assay, with a mean peak response of 198 SFCs per 
million PBMCs (figure 2A). The detected ex vivo 5T4- spe-
cific immune T- cell reactivity was attributed to de novo 
induced responses, and only 2 of 39 patients demonstrated 
pre- existing 5T4 responses, which increased after vacci-
nation (figure 2A). The standard heterologous regimen 
(ChAdOx1- MVA- MVA 5T4, 4- week interval) induced an 
antigen- specific response in 4 of 5 (80%) patients, and 
the standard homologous regimen (MVA- MVA- MVA 5T4, 
4- week interval) in 4 of 6 (66.7%) patients, with an overall 
immune response rate of 73%. In the accelerated heter-
ologous regimen (ChAdOx1- MVA 5T4, 1- week interval), 
17 of 28 (61%) patients showed cellular responses to 5T4. 
The magnitude of antigen- specific immune response 
was not significantly different between standard homol-
ogous and heterologous vaccination regimens, perhaps 
due to the small number of patients in these arms 
(figure 2B). In other indications, the T- cell immunoge-
nicity of ChAd- MVA regimens is consistently higher than 
that of homologous MVA regimens.25 26 Also, comparable 
frequencies of antigen- specific T cells were observed 
following the standard heterologous and accelerated 
heterologous immunization schedules (figure 2B), as has 
been observed for other vaccinations such as Ebola.16 The 
CTX preconditioned arms did not show any increase in 
the magnitude of circulating T- cell responses compared 
with the vaccine- only arms (figure 2C). Importantly, 
immunizations against the 5T4 protein elicited T- cell 
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Figure 2 Ex vivo IFN-γ ELISpot responses. Vaccine immunogenicity was assessed by ex vivo IFN-γ ELISpot on freshly 
isolated peripheral blood mononuclear cells (PBMCs) stimulated with 8 pools of overlapping peptides covering the entire 
5T4 protein sequence. Values of spot- forming cells (SFCs) per million PBMCs correspond to the sum of the responses to the 
single pools. (A) Dot plot representing peak responses for each individual patient compared with baseline (BL), pre- vaccination 
responses. Lines represent mean; the paired t- test p value is shown. (B) Comparison of peak responses in patients receiving 
homologous standard vaccination (MVA- MVA- MVA 5T4: MMM), heterologous standard vaccination (ChAdOx1- MVA- MVA 
5T4: CMM) and heterologous accelerated vaccination regimes (ChAdOx1- MVA 5T4: CM), irrespective of cyclophosphamide 
(CTX) preconditioning. Lines represent mean; ns: not significant. (C) Comparison of peak responses between patients without 
CTX preconditioning (−CTX) or receiving CTX course (+CTX) for a week before each immunization, irrespective of vaccination 
regimen. Lines represent mean; ns: not significant. (D) Time- dependent dynamics of cellular responses to individual 5T4 
peptide pools (p1 to p8) in 2 representative patients. Arrows represent time points of vaccination. AS, active surveillance; C, 
ChAdOx1.5T4; M, MVA.5T4; RP, radical prostatectomy.
responses with broad epitope specificities that changed 
over time (figure 2D).
Twenty- six of 39 (67%) patients also mounted 5T4- spe-
cific antibody responses as measured by a relative–quan-
titative ELISA.27 Of note, 5T4 seroconversion occurred in 
all the patients in the standard vaccination regimen arms 
compared with the 46% seroconversion rate in patients 
vaccinated according to the accelerated immunization 
schedules (online supplementary table S3). There was no 
correlation between the induced 5T4- specific antibody 
and T- cell responses (online supplementary figure S2).
In order to evaluate T- cell immune response kinetics, 
patients on the same vaccination schedule were pooled 
irrespective of other variables (ie, CTX status pre- 
treatment, and heterologous or homologous vaccination). 
In patients on the standard schedule, the 5T4- specific 
T- cell response was observed to peak twice: first at 4 weeks 
after priming and second 1 week after the second boost 
(week 9), at a mean of 54±48 SEM and 72 ± 69 SEM SFCs 
per million PBMCs, respectively (figure 3A). This obser-
vation mirrors the immunogenicity of these vectors in 
other indications, where responses post- ChAd peak at 
2–4 weeks and responses post- MVA peak at 1 week. A peak 
T- cell response in patients assigned to the accelerated 
regimen was observed 1 week after the boost at means of 
80 ± 27 SEM in the surgical arm, and 131 ± 85 SEM SFCs 
per million PBMCs in the AS arm (figure 3B). Following 
a contraction phase of the immune response, only weak 
ex vivo responses were detectable at later time points, 
likely because effector cells diminish while less activated 
central memory cells increase.15 Indeed, the repertoire 
of memory 5T4- specific T cells could be expanded by 
short- term in vitro culture in the presence of the total 5T4 
peptide pool from blood samples collected 4–6 months 
after vaccination. Of note, frequencies of expanded 
5T4- specific T cells from blood samples collected prior 
to vaccination from the same patients were usually much 
lower (figure 3D).
Vaccine- induced T- cell responses were further charac-
terized using flow cytometry, which is a less sensitive assay 
than ELISpot and therefore requires an expansion of 
the relatively infrequent antigen- specific T cells. To this 
end, PBMCs from several patients collected at baseline 
and at various timepoints during the study were cultured 
for 12–14 days in presence of the total 5T4 peptide 
pool as previously mentioned. Following in vitro stim-
ulation, cell cultures were stained with fluorochrome- 
labeled antibodies against CD4+ and CD8+ T- cell 
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Figure 3 Kinetics of 5T4 specific responses. Antigen- 
specific responses were measured before vaccination 
and at different time points post- vaccination by ex vivo 
IFN-γ ELISpot assay on freshly isolated peripheral blood 
mononuclear cells (PBMCs). Mean (±SEM) immune 
responses to 5T4 antigen over time are shown irrespective 
of cyclophosphamide preconditioning: (A) in the standard 
vaccination regimen arms; (B) in surgical patients receiving 
the accelerated vaccination regimen; (C) in active 
surveillance patients receiving the accelerated vaccination 
regimen. Arrows represent time points of vaccination. C/M: 
ChAdOx1.5T4 or MVA.5T4; C: ChAdOx1.5T4; M: MVA.5T4. 
(D) Freshly isolated PBMCs from several patients were 
cultured for 2 weeks in the presence of low- dose hIL-2 
and the total 5T4 peptide pool. IFN-γ ELISpot assay was 
performed on cultured cells and baseline responses were 
compared with responses measured at weeks 16 to 24.
surface markers and intracellular IFN-γ and ΤΝF-α cyto-
kines. The gating strategy is presented in figure 4A and 
representative plots of IFN-γ+ΤΝF-α+CD4+ and CD8+ 
T cells on 5T4 stimulation are shown in figure 4B. 
5T4- specific T- cell responses in cultured PBMCs were 
detected in 15 of 21 (71.4%) patients analyzed. Among 
the responders, 5T4- specific CD4+ T- cell reactivity was 
found in 10 (66.7%) patients, CD8+ T- cell reactivity in 
14 (93.3%) patients, and both CD4+ and CD8+ T cell–
mediated responses in 9 (60%) patients (figure 4C). 
Patients displaying a post- vaccination positive immune 
response by flow cytometry also had a low percentage of 
both CD4+ and CD8+ polyfunctional T cells detected at 
baseline (ranges 0.2%–1.8% and 0.01%–0.3%, respec-
tively). However, these numbers at least doubled 
after vaccination, reaching as high as 5.3% and 7.8% 
of 5T4- specific CD4+ and CD8+ T cells at the peak of 
the response (figure 4D). The median fold increase 
of 5T4- specific T- cell responses over baseline values 
amounted to 4.9 and 4.5 in CD4+ and CD8+ T cells, 
respectively (figure 4E). To corroborate the flow cytom-
etry data on induction of both CD4+ and CD8+ 5T4- spe-
cific responses after short- term in vitro stimulation, 
PBMCs from selected responders have been retrospec-
tively thawed to perform CD4+ and CD8+ T- cell deple-
tions and to test the depleted cell fractions in parallel 
with the total PBMCs in an ex vivo IFN-γ ELISpot assay 
(online supplementary materials and methods). As 
shown in online supplementary table S4, nine patients, 
including one non- responder, have been analyzed to 
discriminate between CD4+ and CD8+ T- cell responses 
ex vivo. Among the responders, only four maintained 
the response after freeze/thawing and we could observe 
CD4+ only mediated, CD8+ only mediated, and both 
CD4+ and CD8+ mediated T- cell responses, consistent 
with the results observed by flow cytometry.
Vaccine-induced t-cell responses in the prostate
In order to assess the immune response to the vaccine 
antigen in the target prostate gland, post- vaccination 
tissue cores from RP specimens28 and prostate biopsy 
samples from AS patients were cultured in vitro in order 
to expand TILs and enrich them for 5T4 specificity prior 
to flow cytometric analysis. Immune cell expansion rates 
and CD4+ to CD8+ T- cell ratios varied between patients, 
as well as between tissue fragments derived from the 
same surgical or biopsy specimen. Representative dot 
plots of expanded CD4+ and CD8+ T cells are shown in 
figure 5A. The flow cytometric analysis of TILs was similar 
to that performed on cultured PBMCs. 5T4- specific T- cell 
responses could be detected in the prostate samples of 13 
of 17 patients analyzed (76.5% response rate). Overall, 
prostate tissue analysis demonstrated the presence of 
5T4- specific CD4+ T- cell reactivity in 8 patients (61.5% of 
responders), CD8+ T- cell reactivity in 11 patients (84.6% 
of responders) and both CD4+ and CD8+ T cell–mediated 
responses in 6 patients (46.2% of responders) (figure 5B). 
Percentages of TILs secreting both IFN-γ andΤΝF-α 
measured in two representative patients are shown as a 
comparison between unstimulated and 5T4- stimulated 
cells in figure 5C.
To evaluate post- treatment changes in the immune cell 
infiltration using immunohistochemistry (IHC), tissue 
sections from AS patients were stained with anti- CD3 and 
anti- CD8 monoclonal antibody, and densities of CD3+ 
and CD8+ T cells were assessed by digital image analysis 
as previously described.29 An increase in CD3+ and CD8+ 
T- cell density was observed in the post- vaccination pros-
tate gland in some of the analyzed patients. In particular, 
a ≥1.5- fold increase in CD3+ and CD8+ T- cell density post- 
treatment was detected in 2 out of 11 patients (18%) and 
in 4 out of 11 patients (36%), respectively (online supple-
mentary figure S3).
IHC analysis was also performed on 12 available RP 
tissue sections from patients in groups 1–4, and both 
CD3+ and CD8+ T- cell infiltration was detected in resec-
tion samples (online supplementary table S5). However, 
T- cell densities in the prostate gland following vacci-
nations could not be reliably compared with the pre- 
treatment archival biopsy samples due to technical issues.
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Figure 4 Flow cytometry analysis of 5T4- specific immune responses induced by vaccination. Freshly isolated peripheral 
blood mononuclear cells (PBMCs) were cultured for 2 weeks in the presence of low- dose hIL-2 and the total 5T4 peptide pool 
to expand relatively infrequent 5T4- specific T cells. Flow cytometric analysis was performed on cultured cells at different time 
points, and the percentage of polyfunctional CD4+ and CD8+ secreting IFN-γ+ and TNF-α+ was calculated by subtracting 
background responses (Δ value) and compared with corresponding pre- vaccination values. (A) Representative gating 
strategy. From left to right, top to bottom: time–lymphocytes–single cells–live cells–CD3+ T cells–CD4+ and CD8+ T cells. 
(B) Representative dot plot with percentages showing CD4+ (top) and CD8+ (bottom) T cells secreting IFN-γ+ and TNF-α+. 
(C) Percentages of evaluated patients showing a positive response in cultured PBMCs (gray bar) and relative percentages 
of positivity for CD4+, CD8+, and both CD4+ and CD8+ among responders (black bars). (D) Baseline Δ value percentages 
of IFN-γ+ and TNF-α+CD4+ and CD8+ T cells are compared with corresponding peak Δ value percentages obtained after 
vaccination in each individual patient analyzed. BL: baseline. (E) Fold increase of peak Δ value percentages over baseline of 
polyfunctional CD4+ and CD8+ T cells induced by vaccination are shown. Lines represent median.
serum PsA changes following vaccination
The serum PSA level is commonly used as a surrogate 
marker of PCa treatment efficacy. Potential treatment 
effects of the vaccine on PCa were assessed by measuring 
serum PSA throughout the trial. In the majority of 
patients in the surgical arms, PSA could only be assessed 
at a few time points prior to RP, as this intervention 
ordinarily causes the PSA to drop to very low or unde-
tectable levels. However, patients on the AS program 
could be followed up for 48 weeks, thus changes in PSA 
were monitored in these patients for an extended time 
period. Figure 6A shows PSA changes over time in the 
12 patients in the AS arms. Although there was some 
disparity in the PSA kinetics between patients, the overall 
trend showed an unexpected increase in serum PSA 
concentration after ChAdOx1.5T4 prime with a peak at 
week 4, with PSA decreasing to pre- vaccination levels by 
week 22 (figure 6B). Of note, median peak levels of PSA 
after vaccination were significantly higher than median 
baseline levels (8.25 ng/mL vs 4.16 ng/mL) (figure 6C). 
Analysis of the maximal PSA change detected at any 
given time point post- vaccination demonstrated that 25% 
of the patients had a PSA drop of 12%–38% compared 
with pre- vaccination values and 50% of patients expe-
rienced an increase of 17%–52% over the baseline 
(figure 6D). Notably, 25% of patients had a striking 
≥100% increase in PSA concentration from a baseline 
mean of 3.9±0.5 SD ng/mL to a peak mean of 10.7±1.4 SD 
ng/mL (figure 6D). Importantly, this increase of ≥100% 
in serum PSA levels observed in three patients was asso-
ciated with both peripheral and local biomarkers of 
vaccine immunological activity, such as presence of poly-
functional 5T4- specific CD8+ and CD4+ T- cell responses 
in the blood as measured by ex vivo ELISpot and flow 
cytometry of short- term cultured PBMCs, expansion of 
5T4- specific polyfunctional T cells from fresh prostate 
biopsy samples and a ≥1.5- fold increase in CD8+ T- cell 
infiltration in post- treatment prostate biopsies compared 
with baseline (table 1). T- cell densities measured by IHC 
of two of these three patients are shown in figure 7, as well 
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Figure 5 Flow cytometry analysis of 5T4 specific immune 
responses in the prostate tissue. Post- vaccination prostate 
biopsy samples and radical prostatectomy tissue specimens 
were cultured in the presence of high- dose hIL-2 and 
were stimulated with the total 5T4 peptide pool to expand 
5T4- specific T cells derived from the prostate gland. Flow 
cytometric analysis was performed on expanded tumor- 
infiltrating lymphocytes (TILs) 1 week after 5T4 stimulation. 
(A) Representative flow dot plot showing percentages of 
gated CD4+ and CD8+ TILs obtained from expanded cultures 
in different samples. (B) Percentages of evaluated samples 
showing a positive response in cultured TILs (gray bar) and 
relative percentages of positivity for the CD4+, CD8+ T cell 
and both CD4+ and CD8+ T- cell subsets (black bars). (C) 
Percentages of IFN-γ+ and TNF-α+ TILs (CD4+ and CD8+) 
in unstimulated cultures (R10: medium only) are compared 
with the corresponding 5T4- stimulated cultures (5T4) in 2 
representative patients (VAN-807 and VAN-021). AS, active 
surveillance; RP, radical prostatectomy.
as representative images of IHC staining of the respec-
tive prostate biopsies. The TIL and IHC data for the 
third patient (VAN-022) were not available as his on- study 
biopsy was not performed for clinical reasons.
dIsCussIon
In this study, the safety profile and immunogenicity of 
the first- in- man ChAdOx1- MVA vaccination against the 
5T4 tumor antigen in low- risk and intermediate- risk 
patients with PCa has been evaluated. The vaccine was 
well tolerated in both the standard and accelerated regi-
mens, with the safety profile in agreement with previous 
reports for these viral vectors.13 30 31 Vaccines induced de 
novo 5T4- specific immunity in all but two patients and 
significantly boosted two pre- existing responses. Overall, 
64% of patients were found to have responded to vacci-
nation with a magnitude of response ranging between 30 
and 1025 SFCs per million PBMCs and some responses 
detected as early as after a single priming immuniza-
tion. To our knowledge, this is the best vaccine- induced 
immune response rate obtained to date in any clinical 
trials in patients with PCa measured by ex vivo IFN-γ 
ELISpot assay.
Vaccination- induced 5T4- specific antibody responses 
were detected in all patients in the standard vaccination 
regimen arms, as opposed to 46% of patients following 
the accelerated vaccination protocol. This finding 
suggests that a second MVA boost and/or longer intervals 
between vaccinations are more favorable for induction of 
antibody responses to 5T4.
Available information on breaking tolerance and 
induction of T- cell responses to self- antigens in PCa 
vaccine trials remains sparse. The response rate and 
magnitude of response achieved in the VANCE trial can 
be considered noteworthy when compared with immu-
notherapy responses measured in other clinical trials 
on patients with PCa. However, to date the majority of 
PCa immunotherapy clinical trials have been focused 
on patients with metastatic castration- resistant disease. 
These patients are known to have compromised cellular 
immunity, increased suppressive phenotypes of myeloid- 
derived suppressor cells and regulatory T cells in the 
circulation, and an increased immune suppressive tumor 
microenvironment. These factors have to be taken into 
account when comparing the immune responses elicited 
in the patients with low- risk/intermediate- risk low- volume 
disease recruited to the VANCE study.
The closest comparator for the ChAdOx1- MVA 5T4 
vaccine in the metastatic PCa setting is TroVax, a homol-
ogous MVA 5T4 vaccination regimen.30 In the reported 
phase II trial, 5T4- specific T- cell responses were induced 
in 38% of patients with hormone refractory PCa over the 
course of 11 TroVax immunizations. ProstVac vaccine 
induced PSA- specific T- cell responses in 57% of patients 
across six clinical trials. However, the magnitude of the 
response measured 4 weeks after the last immunization 
was in the range of 10 to 203 SFU per million PBMCs, 
with a median response of 30 SFU per million PBMCs.4 
Recently, ProstVac vaccine has been evaluated in the 
neoadjuvant setting prior to radical prostatectomy in a 
patient cohort similar to the one in the VANCE study.32 A 
direct comparison of the immune responses induced by 
ProstVac and ChAd- MVA vaccines is difficult because of 
the different primary outcome measures and test assays 
applied. Nevertheless, ProstVac vaccination has led to 
increased CD4+ T- cell infiltration in the RP specimens 
compared with pre- treatment biopsies in more than one- 
third of the patients, and 28% of the patients developed 
PSA- specific CD4+ and CD8+ T- cell responses as measured 
by flow cytometry following a period of in vitro stimula-
tion with overlapping PSA peptides.
The licensed cell- based immunotherapy Sipuleu-
cel- T induced T- cell responses to the target antigen, 
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Figure 6 Prostate- specific antigen (PSA) levels in the active surveillance arms. Serum PSA concentration was measured 
throughout the study. Changes in PSA concentration are shown for each individual patient in the active surveillance 
arms (A) and as mean concentrations±SEM (B); paired t- test value p=0.02. Arrows represent time points of vaccination. 
C: ChAdOx1.5T4; M: MVA.5T4. (C) A scatter dot plot graph representing baseline PSA concentrations compared with 
corresponding peak concentrations measured post- vaccination in active surveillance patients. Lines represent median; 
paired t- test value p=0.006. (D) Waterfall plot representing the highest PSA change from baseline, expressed as percentage 
of baseline value, measured at any given timepoint in patients on the active surveillance arms (patient trial IDs are given). * 
represents a systemic immune response to the vaccine measured either by ex vivo IFN-γ ELISpot on freshly isolated peripheral 
blood mononuclear cells (PBMCs) or flow cytometry on short- term stimulated PBMCs. # indicates a CD8+ T- cell local immune 
response to the vaccine measured either by flow cytometry on short- term stimulated tumor- infiltrating lymphocyte cultures or 
by immunohistochemistry on post- vaccination biopsies (CD8+ T- cell density ≥1.5- fold pre- vaccination biopsies).
a recombinant fusion protein of PAP and GM- CSF 
(PA2024), in 48% of patients with treated mCRPC 
compared with 6% in the control group. However, the 
response rate to the PAP antigen itself was in the range 
of 6%–8% in both treated and control patients,3 which 
suggests that much of T- cell reactivity against the recom-
binant protein may have been directed to the junctional 
foreign antigens. In another clinical trial, a DNA vaccine 
encoding PAP and GM- CSF (pTVG- HP) was assessed for 
immunogenicity in patients with PCa with biochemical 
recurrence. This vaccine yielded a low response rate of 
14%.33 A follow- up study demonstrated that PAP- specific 
T cells could be detected after a course of six vaccina-
tions.34 The pTVG- HP vaccine has been evaluated more 
recently in mCRPC in combination with anti- PD1.35 The 
reported T- cell responses were likely to be predomi-
nantly CD4+ T cell mediated, as the PAP protein induced 
much higher frequencies of PAP- specific T cells by 
IFN-γ ELISpot compared with the PAP peptide antigen. 
Also, the responses to PAP peptides were detected after 
48–72 hours of in vitro re- stimulation, in contrast to the 
standard 18- hour assay used here. An RNA- based vacci-
nation approach has also been evaluated in mCRPC.36 
The self- adjuvanted mRNA vaccine CV1903 against four 
prostate antigens induced T- cell responses in 55% of 
patients. These responses were detected after six doses 
of the vaccine and reported as a cumulative response 
rate measured by MHC class I tetramer staining, ICS and 
IFN-γ ELISpot.
CTX preconditioning did not have a detectable effect 
on the magnitude of 5T4- specific response. This obser-
vation was unexpected, as low- dose CTX may selectively 
suppress regulatory T cell (Treg) number and function-
ality, without influencing other T- cell subsets.37 However, 
the little impact from CTX observed here is corrobo-
rated by other studies. For example, depletion of Tregs 
with low- dose CTX prior to vaccination did not increase 
immune responses generated by MVA.5T4 vaccination in 
patients with metastatic colorectal cancer.38
We observed the presence of vaccine- induced systemic 
CD8+ or/and CD4+ T- cell responses and also detected 
CD8+ T- cell infiltration into the prostate by IHC. 
























































































































































































































































































































































































































































































Interestingly, in contrast to observations seen in other 
malignancies, a positive correlation between the density 
of tumor- infiltrating CD8+ T cells and improved clinical 
outcome remains controversial in PCa.39 On one hand, 
it has been suggested that abundant TILs in the prostate 
gland are associated with a higher survival probability.40 
On the other hand, high numbers of TILs within the 
tumor have been predictive of an increased risk of tumor 
recurrence in patients undergoing RP.41 42 In addition, 
a strong TIL presence was an independent predictor 
of short PSA recurrence- free survival.43 More recently, 
higher levels of primarily CD4+ T cells and, to a lesser 
extent, CD8+ T cells, appeared to be associated with a 
worse distant metastasis- free survival.44 These reports 
suggest that in addition to enumerating T cells in the 
prostate tumor, the functional status and tumor speci-
ficity of TILs after vaccination are important characteris-
tics to analyze. To this end, in the VANCE study, we made 
use of fresh post- vaccination prostate tissue for quanti-
tative assessment of 5T4- specific polyfunctional TILs in 
addition to IHC analysis of fixed tissue. Of note, 11 of 
13 (85%) patients demonstrated presence of functional 
CD8+ T cells, with over 50% of these patients exhibiting 
a concomitant CD4+ T- cell response. A limitation of our 
approach is that the TILs subjected to this functional 
analysis have been cultured in vitro, isolated from the 
natural tumor immunosuppressive microenvironment, 
and so they might have expanded in a more favorable 
environment. Another drawback of our analysis is that it 
was not possible to compare the immune cell phenotype 
and function in the prostate gland pre- vaccination and 
post- vaccination, due to the unavailability of fresh tissue 
before study treatment.
The presence of 5T4- reactive TILs might also explain 
the transient increase in PSA levels observed in AS patients 
post- vaccination. Although the observed PSA trends 
post- vaccination were variable, three AS patients (25%) 
experienced a transient PSA rise of ≥100% that cannot 
be explained by physiological variations or inter- test vari-
ability. The herein hypothesized correlation between PSA 
rise and the local vaccine- specific T- cell reactivity remains 
to be investigated further. However, to corroborate our 
speculation, a “PSA bounce” observed after brachytherapy 
in localized PCa correlated with higher densities of CD3+ 
and CD8+ T cells within the tumor, suggesting that local 
immune response was responsible for the PSA bounce 
observed in the analyzed cohort of patients with early 
PCa.45
ConCLusIons
The heterologous ChAdOx1- MVA 5T4 vaccination 
regimen in early- stage PCa was found to be both safe 
and immunogenic, with the majority of patients with PCa 
enrolled in this trial mounting ex vivo T- cell responses 
to the vaccine- encoded tumor- associated antigen 5T4. 
Immune responses mediated by polyfunctional CD8+ 
and CD4+ T cells could be detected following vaccination 
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Figure 7 T- cell infiltration in the prostate. Archival diagnostic prostate biopsies and matched on- study prostate biopsies taken 
at week 10 from selected patients in the active surveillance arms were tested for T- cell infiltration by immunohistochemistry 
(patient trial IDs are given). Formalin- fixed paraffin- embedded sections were stained with anti- CD3 and anti- CD8 antibodies 
and cell densities were calculated. (A) Comparison of CD3+ (left) and CD8+ (right) T- cell densities, expressed as number of 
cells/mm2, and (B) representative pictures of CD3 and CD8 expression between pre- treatment and post- treatment biopsies 
in 2 patients who had ≥100% increase in serum prostate- specific antigen levels post- vaccination. Brown regions indicate 
immunoreactivity. Scale bar is shown (100 µm).
ex vivo in the blood and following in vitro culture of 
cells obtained from prostate tissue. The transient rise 
in serum PSA observed post- vaccination, which signifi-
cantly exceeded physiological variation in some patients, 
supports a possible vaccination effect within the prostate 
gland.
It remains to be seen if the vaccination strategy 
presented herein generates immune responses of suffi-
cient magnitude to mediate clinical efficacy and whether 
it can be effective in later- stage PCa therapeutic settings, 
as a monotherapy in advanced disease or as part of 
multi- modality PCa therapy. To address these questions, 
we have started the phase I/II trial ADVANCE, which 
is currently recruiting patients with intermediate- risk 
PCa, and patients with advanced mCRPC, to receive 
ChAdOx1- MVA 5T4 vaccine in combination with 
nivolumab (NCT03815942).
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